Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index
In this study of premenopausal women with hormone receptor-positive breast cancer, BCI (H/I) status did not clearly predict greater benefit of adjuvant exemestane plus OFS vs tamoxifen plus OFS for women with BCI (H/I)-low tumors than for those with BCI (H/I)-high tumors; BCI continuous indices were reconfirmed as prognostic for premenopausal women. These findings support prior results of SOFT, which compared tamoxifen-alone vs OFS with either exemestane or tamoxifen, indicating premenopausal patients with BCI (H/I)-low tumors may benefit from more intensive endocrine therapy.
Authors
- Catherine A. Schnabel (ORCID: https://orcid.org/0009-0006-5500-9290)
- Yue Ren (ORCID: https://orcid.org/0009-0003-4777-3342)
- Matthew P. Goetz (ORCID: https://orcid.org/0000-0002-4383-270X)
- Fabio Puglisi (ORCID: https://orcid.org/0000-0003-0573-4938)
- Claudio Chini
- Meredith M. Regan (ORCID: https://orcid.org/0000-0002-2428-6109)
- Eva Ciruelos
- Prudence A. Francis (ORCID: https://orcid.org/0000-0002-7207-9286)
- Natalia Siuliukina
- Barbara Walley (ORCID: https://orcid.org/0000-0002-9618-905X)
- Khalil Zaman
- Elisabetta Munzone (ORCID: https://orcid.org/0000-0003-3371-3878)
- Gini F. Fleming (ORCID: https://orcid.org/0000-0003-2845-4023)
- Carlo Tondini (ORCID: https://orcid.org/0000-0003-0635-8954)
- Ruth O’Regan
- Henry Gómez (ORCID: https://orcid.org/0000-0003-2660-1843)
- Roswitha Kammler (ORCID: https://orcid.org/0000-0002-5572-7894)
- Marco Colleoni (ORCID: https://orcid.org/0000-0002-5743-3013)
- Vered Stearns (ORCID: https://orcid.org/0000-0003-4018-4708)
- Kai Treuner (ORCID: https://orcid.org/0009-0006-3443-3578)
- Hervé Bonnefoi (ORCID: https://orcid.org/0000-0003-4293-9748)
- Patrizia Dell’Orto (ORCID: https://orcid.org/0000-0001-9166-0829)
- Charles E. Geyer (ORCID: https://orcid.org/0000-0002-2379-5702)
- Olivia Pagani (ORCID: https://orcid.org/0000-0001-9739-6299)
- Sibylle Loibl (ORCID: https://orcid.org/0000-0001-6488-4958)
- Yi Zhang (ORCID: https://orcid.org/0009-0004-6107-2232)
- Muhammad Salim (ORCID: https://orcid.org/0009-0009-7454-6018)
- G. Viale
- Sherene Loi
- Stefania Vittoria Luisa Nicoletti
- István Láng
- Silvana Martino
Institutions
- Goethe University Frankfurt (DE)
- University of Udine (IT)
- Harvard University (US)
- Université de Bordeaux (FR)
- Inserm (FR)
- The University of Melbourne (AU)
- University of Calgary (CA)
- Queen's University (CA)
- Cornell University (US)
- Alliance for Clinical Trials in Oncology (US)
- Peter MacCallum Cancer Centre (AU)
- Ospedale di Circolo e Fondazione Macchi (IT)
- Research Institute Hospital 12 de Octubre (ES)
- St Vincent's Hospital Melbourne (AU)
- University of Chicago Medical Center (US)
- Breast Cancer Trials (AU)
- Cancer Trials Australia (AU)
- Angeles Clinic and Research Institute (US)
- University Hospital of Geneva (CH)
- Ospedale Papa Giovanni XXIII (IT)
- Biothera (United States) (US)
- Dana-Farber Cancer Institute (US)
- Hologic (United States) (US)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- National Cancer Institute (UA)
- European Organisation for Research and Treatment of Cancer (BE)
- UPMC Hillman Cancer Center (US)
- Centro di Riferimento Oncologico (IT)
- Ospedale Infermi di Rimini (IT)
- German Breast group (DE)
- Institut Bergonié (FR)
- University of Pittsburgh Medical Center (US)
- Swiss Group For Clinical Cancer Research (CH)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- International Breast Cancer Study Group (CH)
- NRG Oncology (US)
- NSABP Foundation (US)
- SWOG Cancer Research Network (US)
- BoRdeaux Institute of onCology (FR)
- University of Rochester (US)
- Università della Svizzera italiana (CH)
- European Institute of Oncology (IT)
- University of Lausanne (CH)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.40931
- Citations
- 2
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Breast Cancer Research Foundation
- Pfizer
- AstraZeneca
- American College of Radiology Imaging Network
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
- BioTheranostics
- Oncosuisse
- Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
- Ipsen
- National Institutes of Health
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute